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Abstract
Background: Cumulating evidence from rodent models points to a pathophysiological role of inflammatory
signaling in the epileptic brain with Toll-like receptor-4 signaling acting as one key factor. However, there is an
apparent lack of information about expression alterations affecting this pathway in canine patients with epilepsy.
Therefore, we have analyzed the expression pattern of Toll-like receptor 4 and its ligands in brain tissue of canine
patients with structural or idiopathic epilepsy in comparison with tissue from laboratory dogs or from owner-kept
dogs without neurological diseases.
Results: The analysis revealed an overexpression of Toll-like receptor-4 in the CA3 region of dogs with structural
epilepsy. Further analysis provided evidence for an upregulation of Toll-like receptor-4 ligands with high mobility
group box-1 exhibiting increased expression levels in the CA1 region of dogs with idiopathic and structural
epilepsy, and heat shock protein 70 exhibiting increased expression levels in the piriform lobe of dogs with
idiopathic epilepsy. In further brain regions, receptor and ligand expression rates proved to be either in the control
range or reduced below control levels.
Conclusions: Our study reveals complex molecular alterations affecting the Toll-like receptor signaling cascade,
which differ between epilepsy types and between brain regions. Taken together, the data indicate that multi-
targeting approaches modulating Toll-like receptor-4 signaling might be of interest for management of canine
epilepsy. Further studies are recommended to explore respective molecular alterations in more detail in dogs with
different etiologies and to confirm the role of the pro-inflammatory signaling cascade as a putative target.
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Background
Over the last two to three decades, evidence has cumu-
lated pointing to a key pathophysiological role of excessive
inflammatory signaling in the epileptic brain [1, 2]. Experi-
mental data from rodent models confirmed that enhanced
activation of inflammatory pathways can contribute to en-
hanced excitability and lowered thresholds in the epileptic
brain [3–5]. Moreover, increased expression rates of vari-
ous pro-inflammatory mediators have been demonstrated
in brain tissue from rodent epilepsy models as well as hu-
man patients with epilepsy [1, 6–10].
Among these mediators Toll-like receptor (TLR) signal-
ing has been attributed a crucial role [2, 11]. As the best
characterized ligand of TLR4, the danger associated mo-
lecular pattern molecule (DAMP) high mobility group
box 1 (HMGB1) has been intensely studied in rodent
models with induced seizures or spontaneous seizures [3,
12–17]. Enhanced release of HMGB1 proved to reduce
seizure thresholds and increase seizure susceptibility [3,
16]. The effect of the HMGB1 disulphide isoform on ex-
citability were mediated by activation of TLR4. Further
support for an ictogenic property of HMGB1/TLR4 sig-
naling came from a study, which did not only demonstrate
an antiepileptogenic effect but also provided evidence for
an anticonvulsant effect of an inactivating HMGB1 mono-
clonal antibody in two acute seizure models in mice [18].
In addition, earlier studies reported that TLR4 antagonists
exert anticonvulsant effects in two different acute seizure
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models and a chronic epilepsy model [3]. Moreover, in
comparison with wild-type mice TLR4-deficient mice de-
velop less severe epilepsy following status epilepticus [19].
Thus, convincing evidence exists that targeting of TLR4-
signaling pathways might be of particular interest for
management of epilepsy based on disease-modifying
approaches.
As we have previously discussed [20], further ligands of
TLR4 receptors should be considered when developing
strategies preventing TLR4-mediated increases in excit-
ability and seizure susceptibility. In this context, it is of
interest that the inducible heat shock protein 70 (HSP70)
proved to be up-regulated in the hippocampus and para-
hippocampal cortex in a rat post-status epilepticus model
with epilepsy manifestation following a latency period
[20]. HSP70 has been functionally classified as a modula-
tor of TLR4 function [21, 22]. Recently, we confirmed its
relevance in a kindling model, in which mice overexpress-
ing human HSP70 exhibited an increased seizure suscepti-
bility with lowered thresholds and generalized seizure
occurring early during the stimulation paradigm [23].
Canine epilepsy with different etiologies has been sug-
gested as a natural animal model, which can serve as a
translational bridge between testing in highly standardized
rodent models and human clinical studies [24]. However,
so far there is an evident paucity of information about de-
tailed neuropathological alterations in canine epilepsy,
which in particular applies for the question whether rele-
vant inflammatory signaling also occurs in the canine epi-
lepsy with different etiologies. Considering the prominent
role of TLR4-signaling, we have focused this first study on
the analysis of the distribution and expression rates of the
TLR4 ligands HMGB1 and HSP70. Findings in dogs with
structural epilepsy caused by identified cerebral pathology
and idiopathic epilepsy were analyzed separately and com-
pared. In addition, we assessed the impact of recent seiz-
ure clusters or status epilepticus in tissue from subgroups
of dogs, which exhibited repetitive seizure patterns (at
least two seizures per day = cluster) or beginning of con-
tinuous seizure activity during a time span between 1 h
and 5 days before death.
Results
Clinical diagnosis
The first seizure event occurred in a time interval from
1 day to 11 years before the last clinical presentation
prior to death or euthanasia. All dogs included in this
study exhibited convulsive seizures (focal and general-
ized). In the anamnesis, there was no report about
atonic, absence or myoclonic seizures. The seizure fre-
quency varied in a wide range with dogs presenting only
one seizure per month and others presenting seizure
clusters resulting in up to 120 seizures per month.
The underlying lesions of dogs grouped with structural
epilepsy covered a spectrum of four dogs with encephalitis,
three dogs with a brain tumor, two dogs with hydroceph-
alus and one dog each with cerebral infarct, vacuolization
of the frontal white matter and leucoencephalomalacia.
HE stained brain slices were examined to analyze
seizure-induced secondary lesions in the hippocampus
of epileptic animals. Morphological lesions in the hippo-
campus included a segmental vacuolation of the neuropil
in four dogs, a gliosis in two dogs and a granulomatous
inflammation in one dog. In 12 dogs, we did not detect
significant cellular alterations.
For epileptic dogs with very high or very low protein
expression we checked for an association between the
time-gap between the last epileptic seizure and euthan-
asia/death. However, we did not find any coherence.
In addition, we analyzed if the kind of lesion (i.e. en-
cephalitis versus brain tumor) had an effect on protein
expression levels (TLR4, HMGB1, HSP70 and NeuN)
within the group of structural epilepsy. Due to the low
animal numbers within the subgroups, statistical analysis
based on the kind of lesion was only possible for the en-
cephalitis and tumor subgroup. Altogether, the kind of
lesion did not affect protein expression for none of the
analyzed proteins.
Impact of epilepsy on the TLR4-signaling cascade in
canine patients
We analyzed TLR4 expression (optical density (O.D.)) in
the cornu ammonis region (CA) 1, CA3, dentate gyrus,
hilus sub-region of the hippocampal formation, and in
the piriform lobe by immunohistochemistry in canine
brain tissue. In all sub-regions, we detected only very
sparse positive cells that either appear as single cells or
cell clusters. TLR4 positive cells were often associated to
blood vessels or capillaries (see Fig. 1a-d). The intensity
of TLR4 expression in animals with epilepsy was only al-
tered in the CA3 sub-region of the hippocampus of dogs
with structural epilepsy. The respective O.D. exceeded
that in owner kept control dogs by 32% (F (3, 41) = 2.791,
p = 0.0535; CTRpat vs. Structural p < 0.05; see Fig. 1e). In
contrast, TLR4 expression proved to be in the control range
in dogs with idiopathic epilepsy. Our analysis of TLR4 ex-
pression levels did not reveal any significant group differ-
ences in any of the other brain regions (see Table 1).
In addition, we analyzed the expression (O.D. and
positive stained area) of the TLR4 ligand HMGB1 in the
hippocampus (CA1, CA3, dentate gyrus and hilus) and
in the piriform lobe of dogs with epilepsy. The majority
of immunopositive cells exhibited a round to elliptical
shape with a diameter of 4–8 μm and an intense signal.
These cells resemble the shape of microglia cells. A sec-
ond positive stained cell type presented a less intense
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positive signal in the cytoplasm. Considering the morph-
ology, these cells might be neurons (see Fig. 2a-d).
Quantitative analysis of HMGB1 expression tended to
be increased in the CA1 region of the hippocampus,
whereas in CA3, dentate gyrus and hilus HMGB1
expression levels tended to be reduced (see Fig. 2f, k, g,
l, h, m, i, n, j, o).
Quantitative analysis of HMGB1 expression in the
CA1 region confirmed an elevated O.D. in dogs with
idiopathic epilepsy in comparison to control dogs (F (3,
42) = 2.186, p = 0.1051; CTRexp vs. Idiopathic p < 0.05,
see Fig. 2f). The HMGB1-positive area was increased by
81% in animals suffering from structural epilepsy when
compared to control dogs (F (3, 43) = 2.553, p = 0.069;
CTRexp vs. Structural p < 0.05; see Fig. 2k).
In the CA3 sub-region, the HMGB1-positive area was
reduced by 62% in dogs with idiopathic epilepsy when
compared to experimental control dogs (F (3, 37) =
3.983, p = 0.0156, CTRexp vs. Idiopathic p < 0.05; see Fig.
2 l). The interpretation of these data needs to consider
Fig. 1 TLR4 expression in CA3. Hippocampal formation CA3 region representative microphotographs of TLR4-positive stained cells of dogs
belonging to the patient control (a), experimental control (b), structural (c), and idiopathic group (d). TLR4 positive cells are often associated to
blood vessels (a) and they might appear as single cells (a, b, d) or in clusters (c). Quantitative analysis of TLR4 expression (O.D.) in the CA3 region
accordingly to epilepsy type (e) and seizure activity (f). CTRpat: patient control dogs; CTRexp: experimental control dogs; Cluster: dogs with cluster
seizures; Structural: dogs with structural epilepsy; SE: dogs with status epilepticus; Idiopathic: dogs with idiopathic epilepsy. Scale bar 10 μm
Table 1 Statistical data of TLR4 O.D. (Type of epilepsy, statistical
test: one-way ANOVA of variance)
Region F-statistic (df1, df2) P-value
CA1 2.048 (3, 42) 0.1216
DG 0.7244 (3, 40) 0.5434
Hilus 0.9539 (3, 41) 0.4236
Pir 1.027 (3, 30) 0.3944
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that a significant difference exists between the two con-
trol groups, i.e. owner-kept dogs with neurological dis-
ease and experimental control dogs (− 46%; CTRexp vs.
CTRpat p < 0.05, see Fig. 2l).
In the hilus and dentate gyrus of patients with struc-
tural epilepsy, the intensity of the HMGB1 staining
proved to be reduced in comparison with one of the
control groups (hilus: F (3, 41) = 5.605, p = 0.0028;
CTRpat vs. Structural p < 0.05 and dentate gyrus: F (3,
43) = 6.189, p = 0.0015; CTRexp vs. Structural p < 0.05;
see Fig. 2h and i). A direct comparison of dogs with
structural and idiopathic epilepsy in the hilus revealed a
higher staining intensity in the latter group (Structural
vs Idiopathic p < 0.05; see Fig. 2h). An analysis of the
HMGB1-immunopositive area in these regions did not
reveal significant differences (hilus: F (3, 42) = 1.072, p =
0.3722; dentate gyrus: F (3, 43) = 0.7485, p = 0.5297; see
Fig. 2m and n).
In the piriform lobe, the HMGB1-positive area in dogs
with idiopathic epilepsy exceeded that in dogs with
structural epilepsy by 88% (F (3, 36) = 2.09, p = 0.1204,
Structural vs. Idiopathic p < 0.05, see Fig. 2o).
In addition to HMGB1, we analyzed HSP70 expression
in the hippocampus (CA1, CA3, dentate gyrus and hilus)
and in the piriform lobe in brain tissue of dogs with
chronic epilepsy. We observed immunopositive reactivity
in the cytoplasm of cells with a neuronal morphology in
all analyzed brain regions (see Fig. 3b-e).
Quantitative analysis of HSP70 expression (O.D. and
HSP70-positive area) revealed only minor changes in
epileptic dogs (see Fig. 3f-i). The most noticeable change
of HSP70 expression was observed in the hilus with a
Fig. 2 HMGB1 expression in all investigated areas. Representative histological images of HMGB1-positive stained cells in the CA1 region of the
hippocampus of dogs of patient control (a), experimental control (b), structural (c), and idiopathic group (d). The majority of immunopositive cells
are intensely stained and have the morphology of microglia cells. Cells with the morphology of neurons have a less intense staining appearing in
the cytoplasm. Correlation analysis of HMGB1 positive area with age (e). Impact of epilepsy type on HMGB1 expression (O.D. and positive labeled
area) in CA1 (f, k), CA3 (g, l), hilus (h, m), dentate gyrus (DG; i, n), and piriform lobe (Pir; j, o). Impact of seizure activity on HMGB1 expression in
CA1 (p, u), CA3 (q, v), hilus (r, w), dentate gyrus (DG; s, x), piriform lobe (Pir; t, y). All data are given as mean ± SEM; p < 0.05 was considered
statistically significant (*). CTRpat: patient control dogs; CTRexp: experimental control dogs; Cluster: dogs with cluster seizures; Structural: dogs with
structural epilepsy; SE: dogs with status epilepticus; Idiopathic: dogs with idiopathic epilepsy. Scale bar 10 μm
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Fig. 3 (See legend on next page.)
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significant reduction of the HSP70-positive area by 28
and 33% in animals with structural and idiopathic epi-
lepsy, respectively (F (3, 43) = 6.661, p = 0.0009, CTRexp
vs. Structural and Idiopathic p < 0.05; see Fig. 3g). As the
reduction might reflect neuronal loss in this region, we
tested for a correlation between neuronal cell density
and HSP70 expression considering data from control
(CTRexp and CTRpat) and dogs with epilepsy (Structural
and Idiopathic). NeuN / HSP70 expression did not cor-
relate in control animals (Pearson correlation coefficient
r = 0.1661, p = 0.51), but there was a trend for a negative
correlation in epileptic animals (Pearson correlation co-
efficient r = − 0.5275, p = 0.0526).
In the piriform lobe, the O. D of HSP70 was increased
by 78% in animals with idiopathic epilepsy when com-
pared to control animals (F (3, 24) = 3.584, p = 0.031,
CTRexp vs. Idiopathic p < 0.05; see Fig. 3h). For interpret-
ation of these data, it needs to be taken into account that
a direct comparison of the two control groups demon-
strated a difference between data from both control
groups (F (3, 26) = 1.703, p = 0.1943, CTRexp vs. CTRpat
p < 0.05; see Fig. 3i). The analysis of correlation between
HSP70 and NeuN expression in control (CTRexp and
CTRpat) and dogs with epilepsy (Structural and Idio-
pathic) indicated no correlation in CTR (Pearson correl-
ation coefficient r = 0.5372, p = 0.0717) and a negative
trend in dogs with epilepsy (Pearson correlation coeffi-
cient r = − 0.6915, p = 0.0852). In all other brain regions
of interest, we detected no significant differences (see
Tables 2 and 3).
Impact of recent repetitive seizures and prolonged
seizure activity on TLR4 signaling in canine patients
The TLR4 O.D. amounted to higher levels in dogs with
cluster seizures as compared to control dogs (F (3, 39) =
2.408, p = 0.831; CTRpat vs. Cluster p < 0.05; see Fig. 1f).
In none of the other regions of interest, we identified
significant group differences (see Table 4).
In the CA1 region the HMGB1-positive area was in-
creased in animals with cluster seizures (F (3, 42) =
3.522, p = 0.0237; CTRexp vs. Cluster and CTRpat vs.
Cluster p < 0.05, see Fig. 2u). Analysis of HMGB1 stain-
ing intensity and labelled area in CA3 did not confirm
relevant group differences when comparing animals with
epilepsy with the control groups (F (3, 38) = 2.008, p =
0.1307; see Fig. 2q). In this region, the HMGB1-positive
area negatively correlated with age in control animals
(Pearson correlation coefficient r = − 0.4529, p = 0.023,
see Fig. 2e), but not in patients with epilepsy. In the
hilus, we found a reduced O.D. in dogs with status epi-
lepticus (− 9%; F (3, 39) = 5.025, p = 0.0052; CTRexp vs.
SE p < 0.05¸ see Fig. 2r). Moreover, in the dentate gyrus,
the O.D. decreased by 7 and 10% in dogs with cluster
seizures and in dogs with status epilepticus, respectively
(F (3, 42) = 4.828, p = 0.006, CTRpat vs. Cluster and
CTRpat vs. SE p < 0.05; see Fig. 2s). In both regions, the
HMGB1-positive area proved to be in the control range
(hilus: F (3, 41) = 1.262, p = 0.3013, dentate gyrus: F (3,
41) = 1.235, p = 0.3103; see Fig. 2w, x). To analyze if the
reduced HMGB1-positive area might reflect neuronal
loss in this region, we tested for a correlation between
the number of neurons and the HMGB1-positive area.
HMGB1 expression did neither correlate with neuronal
density in control animals (CTRexp and CTRpat: Pearson
correlation coefficient r = − 0.08606, p = 0.7426) nor in
animals with epilepsy (Structural and Idiopathic: Pearson
correlation coefficient r = 0.08736, p = 0.7766). In the
piriform lobe, we detected no differences in HMGB1 ex-
pression (O.D.: F (3, 36) = 0.862, p = 0.4705, HMGB1-
positive area: F (3, 34) = 1.094, p = 0.3662; see Fig. 2t, y).
Whereas the O.D. of HSP 70 expression was un-
affected by recent seizure activity in the hilus (F (3,
42) = 1.848, p = 0.1544, see Fig. 3j), the HSP70-
(See figure on previous page.)
Fig. 3 HSP70 expression in hilus and piriform lobe. Representative histological images of HSP70 negative control (a) and HSP70-positive stained
cells in the piriform lobe of dogs of patient control (b), experimental control (c), structural (d), and idiopathic group (e). Immunopositive signal (in
brown) was detectable from the cytoplasm of neuron-like shape cells. Impact of epilepsy type on HSP70 expression (O.D. and positive labeled
area) in the hilus (f, g) and piriform lobe (Pir; h, i). Impact of seizure activity on HSP70 expression in the hilus (j, k) and piriform lobe (Pir; l, m). All
data are given as mean ± SEM; p < 0.05 was considered statistically significant (*). CTRpat: patient control dogs; CTRexp: experimental control dogs;
Cluster: dogs with cluster seizures; Structural: dogs with structural epilepsy; SE: dogs with status epilepticus; Idiopathic: dogs with idiopathic
epilepsy. Scale bar 10 μm
Table 2 Statistical data of Hsp70 O.D. (Type of epilepsy,
statistical test: one-way ANOVA of variance)
Region F-statistic (df1, df2) P-value
CA1 2.073 (3, 39) 0.1195
CA3 2.055 (3, 35) 0.1240
DG 1.717 (3, 40) 0.1790
Table 3 Statistical data of HSP70 immunopositive area (Type of
epilepsy, statistical test: one-way ANOVA of variance)
Region F-statistic (df1, df2) P-value
CA1 1.138 (3, 40) 0.3452
CA3 0.9353 (3, 33) 0.4347
DG 1.576 (3, 39) 0.2106
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immunopositive area proved to be reduced in dogs with
cluster seizures and status epilepticus (F (3, 42) = 6.946,
p = 0.0007, CTRexp vs. Cluster and CTRexp vs. SE p <
0.05; see Fig. 3k). In the piriform lobe of animals with
recent cluster seizures the HSP70 staining intensity
exceeded that in control animals (F (3, 26) = 1.587, p =
0.2198, CTRexp vs. Idiopathic p < 0.05; see Fig. 3l). In all
other regions (CA1, CA3 and dentate gyrus), recent seiz-
ure activity remained without impact on HSP70 expres-
sion (see Tables 5 and 6). It is emphasized that
differences in HSP70 expression became evident be-
tween both control groups in different brain regions (F
(3, 42) = 1.848, p = 0.1544, CTRpat vs. CTRexp p < 0.05;
see Fig. 3j; F (3, 42) = 6.946, p = 0.0007, CTRpat vs.
CTRexp p < 0.05; see Fig. 3k; (3, 26) = 1.968, p = 0.1469,
CTRpat vs. CTRexp p < 0.05 see Fig. 3m).
Considering differences in the age range between the
control groups, we tested whether HSP70 O.D. corre-
lates with age. The respective analysis did not identify a
correlation between these parameters (Pearson correl-
ation coefficient CA1: r = 0.3565, p = 0.0738; CA3: r =
0.2684, p = 0.1759; dentate gyrus: r = 0.2891, p = 0.1435
and hilus: r = 0.2713, p = 0.1711).
Neurodegeneration in hippocampal CA1 and hilus
We assessed neurodegeneration in the CA1, CA3, hilus
sub-region of the hippocampal formation and in the piri-
form lobe based on NeuN immunolabeled sections (see
Fig. 4).
In the CA1 region, the neuronal cell density was re-
duced by 34% in dogs suffering from idiopathic epilepsy
(F (3, 31) = 2.837, p = 0.0561; CTRpat vs. Idiopathic p <
0.05; see Fig. 4a) when compared to owner kept dogs
without central nervous system diseases. Moreover, the
neuronal cell density was reduced in the hilus of patients
with structural epilepsy by 39% (F (3, 33) = 4.476,
p = 0.0103; CTRpat vs. Structural p < 0.05; see Fig.
4b). Surprisingly, significant differences in hilar neur-
onal cell counts were also observed between both
control groups (27%, (3, 33) = 4.476, p = 0.0103;
CTRexp vs. CTRpat p < 0.05; see Fig. 4b).
Counts of NeuN- immunopositive cells remained un-
affected in epileptic animals in CA3 (F (3, 33) = 2.589,
p = 0.0713; see Fig. 4c) and in the piriform lobe (F (3,
24) = 2.031, p = 0.1404). However, when we directly com-
pared dogs with structural and idiopathic epilepsy, the
cell density in the CA3 region reached significantly
higher levels in the latter group (F (3, 33) = 2.589, p =
0.0713; Structural vs. Idiopathic p < 0.05; see Fig. 4c).
It is known that the amount of neurons change with
age in dogs [25, 26]. As the age of the two control
groups differed significantly (F (3, 47) = 4.815, p =
0.0055; CTRexp vs. CTRpat p < 0.05), we assessed whether
NeuN expression correlates with age in these dogs. In
none of the regions NeuN expression exhibited a correl-
ation with age (Pearson correlation coefficient CA1: r =
− 0.2731, p = 0.2888; CA3: r = 0.003, p = 0.9909; hilus:
r = − 0.1281, p = 0.6123; piriform lobe: r = − 0.023, p =
0.9377).
Finally, we analyzed the impact of acute seizure activ-
ity in patients with recent cluster seizures or a status ep-
ilepticus. Dogs with status epilepticus exhibited a
reduced neuronal cell density in the CA1 region (− 39%;
F (3, 30) = 3.089, p = 0.0434; CTRpat vs. SE p < 0.05; see
Fig. 4g) and in the hilus (− 38%; F (3, 32) = 2.754, p =
0.0604; CTRexp vs. SE p < 0.05; see Fig. 4h) when com-
pared to control animals.
Discussion
Analysis of components of the TLR4-signaling cascade
revealed different expression patterns in canine patients
with idiopathic and structural epilepsy. Moreover, ex-
pression analysis in dogs with recent repetitive or long-
lasting seizure events provided evidence for molecular
alterations in TLR4-signaling.
In the brain of different species including humans and
laboratory rodents TLR4 expression has been reported
in microglia and astrocytes with microglia exhibiting
higher expression rates [27]. In the canine brain TLR4
expression has so far only been analyzed in tissue sur-
rounding intracranial meningiomas [28]. The authors
described scattered TLR4-expressing macrophages in the
area of the tumor-brain interface [28]. Here, we now
Table 4 Statistical data of TLR4 O.D. (Recent seizure activity,
statistical test: one-way ANOVA of variance)
Region F-statistic (df1, df2) P-value
CA1 1.397 (3, 42) 0.2569
DG 0.5414 (3, 40) 0.6567
Hilus 1.009 (3, 40) 0.3989
Pir 0.9863 (3, 30) 0.4124
Table 5 Statistical data of HSP70 O.D. (Recent seizure activity,
statistical test: one-way ANOVA of variance)
Region F-statistic (df1, df2) P-value
CA1 1.705 (3, 39) 0.1818
CA3 1.875 (3, 34) 0.1524
DG 1.601 (3, 39) 0.2047
Table 6 Statistical data of HSP70 immunopositive area (Recent
seizure activity, statistical test: one-way ANOVA of variance)
Region F-statistic (df1, df2) P-value
CA1 0.8182 (3, 39) 0.4917
CA3 0.8163 (3, 32) 0.4944
DG 1.373 (3, 38) 0.2656
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report first data for TLR4 expression in canine patients
with structural or idiopathic epilepsy as well as in dogs
without neuropathological findings. Predominant ex-
pression in microglial cells in the canine brain suggests
that the basal expression pattern seems to be similar to
that reported for other species [27]. Comparison be-
tween groups indicated an induction of TLR4 expression
in the hippocampal CA3 region of dogs with structural
epilepsy, whereas TLR4 expression proved to be in the
control range in dogs with idiopathic epilepsy. Higher
TLR4 expression rates might thus constitute a long-term
consequence of an initial epileptogenic insult resulting
in development of structural epilepsy in canine patients.
Increased expression levels might result in excessive in-
flammatory signaling in dogs with structural epilepsy
taking into account that TLR4 activation results in
enhanced generation and release of pro-inflammatory
cytokines including interleukin-1β and tumor-necrosis
factor α [29–31]. A series of previous studies have dem-
onstrated in rodent models that both cytokines can con-
tribute to enhanced excitability, thereby triggering
ictogenesis [1, 11, 32–34].
HMGB1 acts as a danger associated molecular pattern
molecule released from astrocytes and neurons that acts
as one of the main ligands and activators of TLR4. Its
regulation has been reported in hippocampal specimen
from human patients with epilepsy related to different
etiologies as well as in rodent models of epilepsy [13, 17,
35–37]. In the present study, we obtained evidence for
an upregulation of HMGB1 expression in the CA1 re-
gion of dogs with idiopathic and structural epilepsy. The
increase in O.D. versus labelled area in the groups with
Fig. 4 Neurodegeneration in CA1 and hilus. Analysis of NeuN cell density (number of cells per mm2) in the CA1 (a), hilus (4b) and CA3 (c) of the
hippocampal region considering the type of epilepsy. All data are given as mean ± SEM; p < 0.05 was considered statistically significant (*).
Hippocampal formation CA1 region representative microphotographs of dogs belonging to the patient control (d), structural (e) and idiopathic
group (f). Analysis of NeuN cell density (number of cells per mm2) in the CA1 (g), hilus (h) and CA3 (i) of the hippocampal region considering
recent seizure activity. All data are given as mean ± SEM; p < 0.05 was considered statistically significant (*). CTRpat: patient control dogs; CTRexp:
experimental control dogs; Cluster: dogs with cluster seizures; Structural: dogs with structural epilepsy; SE: dogs with status epilepticus; Idiopathic:
dogs with idiopathic epilepsy. Scale bar 25 μm
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different epilepsy types, suggest that the upregulation is
related to an increase in the expression rate per cell in
idiopathic epilepsy and an expansion of the cell popula-
tion expressing HMGB1 at levels above detection
threshold in structural epilepsy. The fact that antagon-
ism of HMGB1 exerted anticonvulsant and antiepilepto-
genic effects in various rodent studies [3, 16, 38, 39]
suggests that increases in HMGB1 observed in the CA1
region might promote seizure generation in canine epi-
lepsy. Thus, pharmacological targeting of HMGB1 might
also be of interest for management and prevention of ca-
nine epilepsy.
In this context it needs to be taken into account that
the induction proved to be limited to the hippocampal
CA1 region, which contrasted with the reduction of
HMGB1 expression observed in other brain regions of
interest. Moreover, it has been described that the func-
tional consequences of HMGB1 signaling largely depend
on the molecular isoform of HMGB1 and the intracellu-
lar translocation [37, 40]. In this context, it is of particu-
lar interest that a recent study confirmed that the
pathologic disulfide HMGB1 isoform might serve as a
mechanistic biomarker for epilepsy development and
early epilepsy manifestation in rodent models and pa-
tients [37]. Thus, it is of future interest to complete
more detailed analysis applying techniques, which allow
to study the ratio between HMGB1 isoforms in the brain
tissue from dogs with epilepsy.
As mentioned above, HSP70 serves as another modu-
lator of TLR4-associated signaling [21, 22], which proved
to be up-regulated in a post-status epilepticus model in
rats. Therefore, the overexpression of HSP70 observed
in the piriform lobe of dogs with idiopathic epilepsy
might trigger TLR4-associated inflammatory signaling in
this brain region. Considering the key role of this signal-
ing cascade with generation of pro-inflammatory cyto-
kines contributing to excessive excitability, targeting of
HSP70 function or expression is suggested as another
anti-inflammatory therapeutic concept for management
of canine idiopathic epilepsy. This conclusion is sup-
ported by recent findings from our group [23]. In this
study genetic overexpression of human HSP70 in mice
resulted in a higher seizure susceptibility [23]. Again, it
needs to be taken into account that enhanced expression
was only evident in one brain region. Therefore, multi-
targeting approaches modulating different molecular
mediators might be more efficacious as compared to
specific targeting strategies affecting a sole pro-
inflammatory mediator. This conclusion is in line with
previous discussions about combined anti-inflammatory
treatment concepts as a basis for efficacious disease-
modifying concepts [41–43].
In contrast to the finding for idiopathic epilepsy,
HSP70 expression proved to be unaffected or decreased
in brain regions of dogs with structural epilepsy. This re-
sult suggests that modulation of HSP70 function or ex-
pression does not constitute a promising strategy for
treatment of this epilepsy type in canine patients.
Taking into account that induction of repetitive occur-
rence of seizures as well as prolonged seizure activity in
laboratory rodents can trigger very pronounced molecu-
lar alterations including induction of different inflamma-
tory signaling molecules [20, 44–46], we have
additionally assessed expression patterns in dogs with re-
cent seizure clusters or status epilepticus. The respective
canine patients either died during seizures or were eu-
thanized as a consequence of intractable epilepsy or
drug-refractory status epilepticus.
Analysis of TLR4 expression revealed an induction in
the hippocampal CA3 region in both subgroups, i.e. dogs
with recent seizure clusters and status epilepticus.
Thereby the increase in patients with seizure clusters
was rather related to an upregulation of expression rates
per cell, whereas the increase in patients with status epi-
lepticus seems to be associated with an expansion of the
population of cells expressing TLR4 above control level.
With regard to expression of TLR4 ligands, a difference
to control was only evident in animals with cluster sei-
zures with an upregulation of HMGB1 in the hippocam-
pal CA1 region and of HSP70 in the piriform cortex.
These data indicate that induction of these TLR4 acti-
vators can further promote excessive inflammation as a
consequence of cluster seizures. However, it needs to be
considered that with the use of post mortem tissue one
cannot distinguish exactly between the impact of the
underlying chronic disease and its etiology on one hand
and the impact of recent repetitive or prolonged seizure
activity on the other hand. In a recent proteomic study
in rats, we have reported an early induction of HMGB1
in the hippocampus and of HSP70 in the hippocampus
and parahippocampal cortex as a consequence of an
electrically-induced status epilepticus [20]. Moreover, a
status epilepticus-associated increase in HMGB1 has
been reported in various other models in rats and mice
[16, 47, 48].
The lack of increased HMGB1 and HSP70 in tissue
from dogs with status epilepticus, is in apparent contrast
to the experimental findings suggesting relevant species
differences. Moreover, it needs to be taken into account
that experimental rodent studies are in general per-
formed in a highly standardized manner, whereas a var-
iety of factors can influence molecular expression rates
in studies focusing on post mortem tissue from patients.
Along this line, immunohistochemistry studies in pa-
tient tissue are often limited by the lack of appropriate
control tissue. Considering different confounding fac-
tors, we have used tissue from two control groups for
comparison with the epilepsy groups. The first batch
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came from patients with exclusion of neurological symp-
toms and lack of any neuropathological alterations. In
this group of patients, we considered that hypoxic
events, which can occur during agony related to different
causes of death or to euthanasia, can affect heat shock
protein expression rates [49–51].
Thus, we have introduced a second control group with
tissue from experimental dogs that have previously been
used in parasitology research. In this group the lower
age range and a putative impact of previous parasite ex-
posure needs to be taken into account for any compara-
tive evaluation. A limitation might be that we do not
know if this has an effect itself. However, even if these
dogs were used for experiments before, their brains were
free of a neuropathology and there were no findings of a
general pathology in the periphery. Furthermore, all of
these dogs were euthanized and right afterwards dis-
sected. Thus, interference of extended time between
death and brain removal or an influence of an extended
agony phase can be excluded. This is in apparent con-
trast to the patient control group with owner kept dogs.
Of course, these dogs were also free of a neuropathology.
However, not all of them have been euthanized and
blood-brain-barrier permeability can be already affected
by hypoxia during agony and this might have an impact
on the expression levels of the analyzed proteins.
We expected to see differences between the two con-
trol groups due to the lack of standardization of the pa-
tient control group. This group might be the better
control for a direct comparison with the epileptic ani-
mals. Nevertheless, we also wanted to explore the effect
of standardization itself and the respective impact in dir-
ect comparison to the epilepsy groups. The consider-
ations received confirmation by the fact that differences
between these control groups became evident with dif-
ferent analysis including that of HSP70 expression.
These differences need to be taken into account when
comparing with tissue from dogs with epilepsy. In this
context, we would like to point out that the increase in
CA1 HMGB1-positive area in dogs with cluster seizures
constituted the only difference evident in comparison
with both control groups.
In this context, age should be considered as a putative
confounding factor. The finding that age correlated
negatively with HMGB1 expression in the hippocampal
CA3 region, suggests that an influence of age should be
taken into account for HMGB1 analysis. Surprisingly,
the direction of correlation is in contrast to previous
findings from aged rats [52] indicating that species dif-
ferences might exist regarding age-related development
of HMGB1 expression.
Molecular alterations analyzed based on labelled area
can be affected by cell loss. In view of a decrease of
HSP70 expression in some brain regions of canine
patients, we therefore additionally analyzed the impact
of epilepsy on neuronal cell density. Disease-associated
neuronal cell loss became evident in the CA1 region of
dogs with idiopathic epilepsy. This outcome is unex-
pected in view of the fact that hippocampal cell loss in
pyramidal layers is considered a hallmark of structural
epilepsy of different etiologies rather than a characteris-
tic feature of idiopathic epilepsy [53, 54]. However, high
seizure frequencies and frequent status epilepticus have
been reported in some dog breeds with a high preva-
lence of idiopathic epilepsy [55]. These might have con-
tributed to CA1 neuronal cell loss as also substantiated
by reduced cell counts in dogs with recent status
epilepticus.
In dogs with structural epilepsy, the difference was
only evident in comparison with the experimental con-
trols. Thus, this finding needs to be interpreted with
some caution, although correlation analysis argued
against age as a confounding factor for hilar neuronal
cell density.
Conclusions
In conclusion, expression analysis of TLR4 and its li-
gands revealed complex changes, which differ between
epilepsy types in canine patients. The regional up-
regulation of the receptor and its ligands suggests that
different molecular alterations might cause enhanced
TLR4-signaling in different brain regions. Taken to-
gether, the data indicate that multi-targeting approaches
modulating TLR4-signaling might be of interest for
management of different types of canine epilepsy. Fur-
ther studies are recommended to explore respective mo-
lecular alterations in more detail in dogs with different
etiologies of epilepsy and to confirm the role of the pro-
inflammatory signaling cascade as a putative target.
Methods
Animals and tissues
In this study, brain tissue of 48 dogs with an age range
of 2 months to 15 years has been collected and proc-
essed as described earlier [56]. A subgroup of dogs was
previously used as experimental dogs in parasitology re-
search by the Institute of Parasitology of the University
of Veterinary Medicine Hanover, Germany. These dogs
are Beagle dogs kept in groups indoors in environmen-
tally controlled rooms. They had free access to partly
roof-covered outside runs. Animals were fed an age ap-
propriate commercial dog diet at a recommended rate,
had free access to water and got rubber toys for environ-
mental enrichment. The previously performed studies in
these dogs by the Institute of Parasitology are not con-
tent of this study and all brain samples used for this
study were taken post mortem. This group was included
as a separate control group for comparison due to the
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fact that hypoxia in a final disease state and during
agony may cause brain cell stress triggering heat shock
protein expression regardless of the type of the disorder
and cause of natural death in owner kept dogs.
In short: after the death of the dogs (owner kept dogs:
euthanasia or natural death due to different underlying
diseases; experimental dogs: euthanasia), the brains were
removed from the skull and fixed in 10% formalin for 10
days. The brains were cut in blocks, embedded in paraf-
fin wax and cut in transverse three μm sections. Sections
were then mounted on positively charged microscope
slides (Superfrost plus, Menzel-Gläser, Braunschweig,
Germany). Every section contained the hippocampus in
a range from #1360 to #1660 of the canine brain atlas
[57]. Dogs were distributed to different groups: 1st pa-
tient control group (CTRpat) comprising owner kept dogs
without central nervous system diseases (n = 18, age
range 2–180months; mean 70.67 ± 12.58); 2nd the ex-
perimental control group (CTRexp) with inclusion of dogs
without central nervous system diseases (n = 10, age
range 12–16 months; mean 14 ± 0.67) and 3rd epileptic
animals grouped by the type of epilepsy defined by eti-
ology as suggested by the international veterinary task
force [58] in epileptic animals with structural epilepsy
caused by identified cerebral pathology (n = 12, age
range 30–140 months; mean 81.17 ± 12.29) and idio-
pathic epilepsy, subtype unknown cause and no identifi-
cation of structural epilepsy (n = 8, age range 2.5–157
months; mean 51.94 ± 18.82) or by the occurrence of
seizure clusters (n = 9, age range 80–140months; mean
68 ± 15.63) or status epilepticus (SE, n = 4, age range 36–
120 months; mean 67.75 ± 20.15) occurring in a time
span of 1 h to 5 days before death.
The grouping of epileptic dogs was based on the clin-
ical diagnosis (anamnesis, neurological examination and
pathological evaluation).
In this study, we decided to have two control groups
with a patient control group and an experimental con-
trol group, which is more homogenous regarding several
characteristics (same breed, similar age, same exposures/
similar environment, standardized food and water, etc.).
In the latter group, a high level of standardization is
reached. We were interested if the effect of
standardization itself has an impact on the different pro-
tein expression levels and we therefore wanted to add-
itionally compare the experimental group directly to the
epilepsy groups. Following the 3R concept, we aimed to
keep animal numbers as low as possible and therefore
used brain tissue from dogs, which were used in differ-
ent experiments before (see above).
Immunohistochemistry – staining procedures
To analyze seizure-induced secondary lesions in the
brains of epileptic animals a Hematoxylin and Eosin
(HE) staining was performed according to standard pro-
cedures and the hippocampus was examined.
For HSP70, TLR4, HMGB1, and NeuN immunostain-
ing, the paraffin-embedded brain sections were deparaf-
finized and rehydrated. Afterwards, we performed heat
induced epitope retrieval with sodium citrate pH 6 at
80 °C in the water bath for 30 min (for HSP70: 20 min in
the microwave at 760W (Severin 900 + Grill, Severin,
Sundern, Germany)). In the following, sections were
rinsed three times in Tris-buffered saline containing
0.05% Tween-20 (P9416, Sigma-Aldrich, Darmstadt,
Germany; TBST) in cuvettes. All subsequent steps, ex-
cept the washing, were performed in a humidity cham-
ber. For HSP70 immunohistochemistry, we additionally
incubated the sections in 3% H2O2 in Tris-buffered sa-
line (TBS, pH 7) for 15 min. The sections were blocked
with 0.25% casein (Sigma-Aldrich, Darmstadt, Germany)
in TBS and incubated over night at 4 °C with primary
antibody dissolved in antibody diluent (TBS with 0.25%
casein and 0.1% Tween-20, see Table 7). After three
washing steps with TBST in cuvettes, sections were in-
cubated with the respective secondary antibody (see
Table 7) for 60 min at room temperature. For TLR4 and
HMGB1 immunohistochemistry, we next incubated the
sections in 1% H2O2 in methanol for 15 min. Following
washing in TBST in cuvettes, sections were incubated ei-
ther for 30 min in Streptavidin/HRP 1:1400 in TBS (AB_
2337238, Cat # 016–030-084, Jackson/Dianova GmbH,
Hamburg, Germany) for HSP70 immunohistochemistry
or for 60 min in the VECTASTAIN ABC-Peroxidase Kit,
Standard Kit (Vector Laboratories Cat# PK-4000, RRID:
AB_2336818) 1:100 in TBST. Sections were rinsed two
times in TBST and then in TBS. Subsequently, sections
were exposed to 3,3′-diaminobenzidine for 30 min
(0.05% 3,3′-diaminobenzidine (CN75, Carl Roth GmbH
& Co. KG, Karlsruhe, Germany) and 0.01% H2O2) for
HSP70 immunohistochemistry or to SIGMAFAST 3,3′-
diaminobenzidine tablets (D4418-50SET, Sigma-Aldrich
Chemie GmbH, Taufkirchen, Germany) dissolved in bi-
distilled water for TLR4 and HMBG1 immunohisto-
chemistry. We washed all sections two times in TBS and
one time in distilled water and counterstained all sec-
tions with Hemalum solution acidic according to Mayer
(Roth T865, Carl Roth, Karlsruhe, Germany). After an
additional washing step in distilled water, differentiation
was carried out for 15 min under running tap water and
after a final washing step in distilled water, we air-dried
the sections overnight and used Entellan® (107,960,
Merck, Darmstadt, Germany) for cover slipping. For all
stainings, we processed negative controls in parallel
omitting the incubation with the primary antibody. De-
tailed information about primary and secondary anti-
bodies with dilution factors and manufacturing company
can be found in Table 7.
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Immunohistochemistry – image analysis and
quantification
An operator unaware of the group assignment analyzed
HSP70, HMGB1, TLR4, and NeuN expression in the
CA1 and CA3, in the dentate gyrus, in the hilus of the
hippocampal formation as well as in the piriform lobe.
The operator captured up to three images per analyzed
brain region at 200x (HMGB1, TLR4, and NeuN) and
up to five images at 400x (HSP70) magnification with an
Olympus BH2 microscope with a single chip charge-
coupled device (CCD) color camera (Axiocam; Zeiss,
Göttingen, Germany), and an AMD Athlon™ 64 Proces-
sor based computer with an image capture interface card
(Axiocam MR Interface Rev.A; Zeiss, Göttingen,
Germany). Images were analyzed by ImageJ [59] soft-
ware (ImageJ v1.51, RRID:SCR_003070, NIH). Up to
three (200x) / five (400x) visual fields (588.14 ×
440.68 μm / 297.22 × 222.70 μm) were evaluated per
region.
For the analysis of NeuN immunohistochemistry, a
well-trained operator counted positive stained neurons
manually as none of the automatic available options
were applicable. The cell density was expressed as the
number of cells per area of interest in mm2.
HMGB1 and HSP70 expression was analyzed by the
positive stained area per analyzed visual field in percent.
In addition, TLR4, HMGB1 and HSP70 were evaluated
by O.D. analysis. For the analysis of O.D., the operator
performed a calibration for grey values following the in-
structions from the website [60]. With the color decon-
volution plug in (vector H-DAB) an 8-bit RGB image
was generated and we used color 2 (brown) for further
analysis. For each staining, we used slightly modified
protocols to meet the optimal analysis conditions.
For the evaluation of HMGB1 immunohistochemis-
try thresholds were set manually (CA1: 0.27, CA3:
0.32, dentate gyrus: 0.23, hilus: 0.33 and piriform
lobe: 0.32) by measuring one visual field per group.
From the obtained values a mean was computed and
applied for the analysis. The dentate gyrus and the
CA1 region have been analyzed twice as the first
thresholds (dentate gyrus: 0.17 and CA1 0.23) proved
to be not strict enough. For the analysis of TLR4
immunohistochemistry, the automated Intermodes
threshold method [61] and for HSP70, the automated
Triangle threshold method [62] was applied for all re-
gions. We computed means from all obtained values
for the individual animals and used them for statis-
tical analysis.
Statistics
For the statistical analysis of group differences, we used
GraphPad Prism 5.04 for Windows (GraphPad Prism
Software, San Diego, USA). We analyzed group differ-
ences of the O.D., positive stained area and cell density
by one-way analysis of variance followed by Bonferroni
Multiple comparison test of selected pairs. We used the
correlation analysis of Pearson to investigate an associ-
ation of the neuronal cell density and HMGB1 expres-
sion and of HSP70 expression in the hilus as well as for
age and NeuN, TLR4, HMGB1 and HSP70 expression.
We applied the Grubbs’ test to detect significant outliers
and considered a p value < 0.05 statistically significant.
All descriptive statistics are expressed as mean ± SEM.
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